The role of CRF as an anorexigenic hormone may involve the NPY, melanocortin and CART systems, acting in a downstream fashion
Important factors affecting GLP-1 market demand and take-up include: The need for better long-term data on the safety and efficacy of use for the designated indications The rapidly expanding list of potential new indications for the drugs, including chronic kidney disease, broader cardiovascular risk reduction, metabolic liver disease, and Alzheimer's disease The number of similar drugs in the development pipeline Price point versus competition, which affects affordability and insurance coverage Marketing efforts of the manufacturers, supply and distribution constraints
The flameout of Pfizer's internally generated GLP-1 candidate was a major setback
Important to remember: that HbA1c result comes from diabetes research, as Rybelsus, the oral semaglutide tablet, is authorised for type 2 diabetes, although, like Ozempic, it is also used off-label for weight loss
